Articles producció científica> Medicina i Cirurgia

Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients

  • Datos identificativos

    Identificador: imarina:9162447
    Autores:
    Watts, Gerald F.Catapano, Alberico L.Masana, LuisZambon, AlbertoPirillo, AngelaTokgozoglu, Lale
    Resumen:
    The widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have reviewed the LDL-C goals and recommend an LDL-C reduction of at least 50% and a goal of <55 mg/dL or even <40 mg/dL. Recent clinical trials have shown that patient stratification based on the presence or absence of atherothrombotic risk factors may represent a valuable tool to identify patients at extremely high CV risk who may benefit more from an aggressive LDL-C-lowering approach. In these patients it may be appropriate to aim for the lowest LDL-C level, independently of recommended goals, with all the available pharmacological approaches. (c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • Otros:

    Autor según el artículo: Watts, Gerald F.; Catapano, Alberico L.; Masana, Luis; Zambon, Alberto; Pirillo, Angela; Tokgozoglu, Lale;
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Masana Marín, Luis
    Palabras clave: Hypercholesterolemia High risk patients Cardiovascular disease
    Resumen: The widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have reviewed the LDL-C goals and recommend an LDL-C reduction of at least 50% and a goal of <55 mg/dL or even <40 mg/dL. Recent clinical trials have shown that patient stratification based on the presence or absence of atherothrombotic risk factors may represent a valuable tool to identify patients at extremely high CV risk who may benefit more from an aggressive LDL-C-lowering approach. In these patients it may be appropriate to aim for the lowest LDL-C level, independently of recommended goals, with all the available pharmacological approaches. (c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
    Áreas temáticas: Peripheral vascular disease Medicine (miscellaneous) Medicina iii Medicina i Internal medicine Farmacia Ciências biológicas iii Cardiology and cardiovascular medicine Biotecnología
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    Direcció de correo del autor: luis.masana@urv.cat
    Identificador del autor: 0000-0002-0789-4954
    Fecha de alta del registro: 2023-02-19
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.sciencedirect.com/science/article/pii/S1567568821000088?via%3Dihub
    Referencia al articulo segun fuente origial: Atherosclerosis Supplements. 42 E30-E34
    Referencia de l'ítem segons les normes APA: Watts, Gerald F.; Catapano, Alberico L.; Masana, Luis; Zambon, Alberto; Pirillo, Angela; Tokgozoglu, Lale; (2020). Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. Atherosclerosis Supplements, 42(), E30-E34. DOI: 10.1016/j.atherosclerosissup.2021.01.006
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI del artículo: 10.1016/j.atherosclerosissup.2021.01.006
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2020
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Cardiology and Cardiovascular Medicine,Internal Medicine,Medicine (Miscellaneous),Peripheral Vascular Disease
    Hypercholesterolemia
    High risk patients
    Cardiovascular disease
    Peripheral vascular disease
    Medicine (miscellaneous)
    Medicina iii
    Medicina i
    Internal medicine
    Farmacia
    Ciências biológicas iii
    Cardiology and cardiovascular medicine
    Biotecnología
  • Documentos:

  • Cerca a google

    Search to google scholar